- Home
- COGT vs NKX Comparison
COGT vs NKX Comparison
Compare COGT & NKX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COGT
- NKX
- Stock Information
- Founded
- COGT 2014
- NKX 2002
- Country
- COGT United States
- NKX United States
- Employees
- COGT N/A
- NKX N/A
- Industry
- COGT Biotechnology: Pharmaceutical Preparations
- NKX Finance/Investors Services
- Sector
- COGT Health Care
- NKX Finance
- Exchange
- COGT Nasdaq
- NKX Nasdaq
- Market Cap
- COGT 555.6M
- NKX 581.2M
- IPO Year
- COGT 2018
- NKX N/A
- Fundamental
- Price
- COGT $5.23
- NKX $11.78
- Analyst Decision
- COGT Buy
- NKX
- Analyst Count
- COGT 6
- NKX 0
- Target Price
- COGT $15.20
- NKX N/A
- AVG Volume (30 Days)
- COGT 1.2M
- NKX 109.3K
- Earning Date
- COGT 05-06-2025
- NKX 01-01-0001
- Dividend Yield
- COGT N/A
- NKX 4.37%
- EPS Growth
- COGT N/A
- NKX N/A
- EPS
- COGT N/A
- NKX N/A
- Revenue
- COGT N/A
- NKX N/A
- Revenue This Year
- COGT N/A
- NKX N/A
- Revenue Next Year
- COGT N/A
- NKX N/A
- P/E Ratio
- COGT N/A
- NKX N/A
- Revenue Growth
- COGT N/A
- NKX N/A
- 52 Week Low
- COGT $3.72
- NKX $9.78
- 52 Week High
- COGT $12.61
- NKX $12.00
- Technical
- Relative Strength Index (RSI)
- COGT 60.43
- NKX 36.50
- Support Level
- COGT $4.80
- NKX $11.76
- Resistance Level
- COGT $4.99
- NKX $11.93
- Average True Range (ATR)
- COGT 0.34
- NKX 0.08
- MACD
- COGT 0.10
- NKX -0.02
- Stochastic Oscillator
- COGT 75.81
- NKX 11.11
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
About NKX Nuveen California AMT-Free Quality Municipal Income Fund
Nuveen California AMT-Free Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objectives are to provide current income exempt from regular federal and California income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.